Improving Outcomes in CLL with BTK Inhibitors: Navigating Adverse Events, Sustaining Treatment, and Future Outlook in Relapsed/Refractory Disease

The FDA granted fast track designation to NX-5948 for treating relapsed/refractory Waldenström macroglobulinemia after 2 or more lines of therapy, including a BTK inhibitor.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Here are some of the highlights from this year's 2024 ASH Annual Meeting & Exposition.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Fixed-duration, subcutaneous epcoritamab-bysp achieved durable responses with a manageable safety profile in older patients with newly diagnosed large B-cell lymphoma who are not candidates for anthracycline-based therapy.

Data presented at ASH 2024 showed that tafasitamab led to a progression-free survival of 11.3 months and an overall survival of 24.8 months in patients with relapsed/refractory DLBCL.